Live Breaking News & Updates on Gout Refractory

Stay updated with breaking news from Gout refractory. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

SEL-212 Shows Significant Response Rates, sUA Reductions in Patients with Gout

Investigators believe targeted immunomodulation with SEL-212 may have the potential to introduce a new uricase-based therapy for patients with gout refractory to conventional treatment. ....

United States , San Diego , Herbert Baraf , George Washington University , American College Of Rheumatology , Bone Research , National Institute Of Arthritis , National Institute , Skin Diseases , Gout Refractory , Conventional Treatment , Primary Outcomes , Two Randomized , Double Blind , Multicenter Phase , American College ,

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (2)

75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of. ....

United States , Carsten Brunn , Anders Ullman , Thomas Kudsk Larsenhead , Selecta Biosciences , Guido Oelkers , Peter Traber , Prnewswire Selecta Biosciences Inc , Sobi Investor Relations Team , Exchange Commission , Company Imm , Selecta Biosciences Inc , Head Of Research Development , Chief Medical Officer , Chief Executive Officer , Medical Affairs , Randomized Double Blind , Placebo Controlled Study , Gout Refractory , Conventional Therapy , Inc Selecta Biosciences , Greater Boston , North America , Middle East , Forward Looking Statementsany , Private Securities Litigation Reform Act ,

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (3)

75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of. ....

United States , Carsten Brunn , Anders Ullman , Thomas Kudsk Larsenhead , Selecta Biosciences , Guido Oelkers , Peter Traber , Prnewswire Selecta Biosciences Inc , Sobi Investor Relations Team , Exchange Commission , Company Imm , Selecta Biosciences Inc , Head Of Research Development , Chief Medical Officer , Chief Executive Officer , Medical Affairs , Randomized Double Blind , Placebo Controlled Study , Gout Refractory , Conventional Therapy , Inc Selecta Biosciences , Greater Boston , North America , Middle East , Forward Looking Statementsany , Private Securities Litigation Reform Act ,

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB

/PRNewswire/ Selecta Biosciences, Inc. (NASDAQ: SELB) and Sobi®, today announced positive topline results from the Phase 3 DISSOLVE I & II placebo. ....

United States , Carsten Brunn , Anders Ullman , Blaine Davis , Selecta Biosciences , Thomas Kudsk Larsen , Guido Oelkers , Peter Traber , Sobi Investor Relations Team , Exchange Commission , Company Imm , Selecta Biosciences Inc , Head Of Research Development , Chief Medical Officer , Chief Executive Officer , Medical Affairs , Randomized Double Blind , Placebo Controlled Study , Gout Refractory , Conventional Therapy , Greater Boston , North America , Middle East , Private Securities Litigation Reform Act , Annual Report , Sobi Media ,

Selecta Biosciences (SELB) Reports Phase 3 DISSOLVE Program of SEL-212 Met Primary Endpoint

Selecta Biosciences (SELB) Reports Phase 3 DISSOLVE Program of SEL-212 Met Primary Endpoint
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Carsten Brunn , Anders Ullman , Thomas Kudsk Larsenhead , Selecta Biosciences , Guido Oelkers , Peter Traber , Sobi Investor Relations Team , Exchange Commission , Company Imm , Selecta Biosciences Inc , Head Of Research Development , Chief Medical Officer , Chief Executive Officer , Medical Affairs , Conference Call , Webcast Reminderselecta , Randomized Double Blind , Placebo Controlled Study , Gout Refractory , Conventional Therapy , Inc Selecta Biosciences , Greater Boston , North America , Middle East , Forward Looking Statementsany ,